Cargando…

MON-531 Thyroid Cancer in Saudi Arabia: Clinical and Histopathological Features, Management and Outcome of a Large Series

The incidence of differentiated thyroid cancer (DTC) is increasing worldwide. Most of the available data came from Western populations. Therefore, data from other populations are important for comparison and understanding of the spectrum of DTC worldwide. In Saudi Arabia, DTC is the 3(rd) most commo...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukhtar, Noha, Albalawi, Lina Nasser, Mazi, Sedra, Aljamei, Hadeel Salah, Fadel, Roqyah, Amer, Lama Ghassan, Elsayed, Tarek, AlQarni, Bayan Saeed, Alnasser, Layla, Alanazi, Faisal, Almatar, Ahmed, Alqahtani, Ashwag Sultan, Bohlega, Balsam Saeed, Moria, Yosra, Alzahrani, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209198/
http://dx.doi.org/10.1210/jendso/bvaa046.787
_version_ 1783531019149770752
author Mukhtar, Noha
Albalawi, Lina Nasser
Mazi, Sedra
Aljamei, Hadeel Salah
Fadel, Roqyah
Amer, Lama Ghassan
Elsayed, Tarek
AlQarni, Bayan Saeed
Alnasser, Layla
Alanazi, Faisal
Almatar, Ahmed
Alqahtani, Ashwag Sultan
Bohlega, Balsam Saeed
Moria, Yosra
Alzahrani, Ali
author_facet Mukhtar, Noha
Albalawi, Lina Nasser
Mazi, Sedra
Aljamei, Hadeel Salah
Fadel, Roqyah
Amer, Lama Ghassan
Elsayed, Tarek
AlQarni, Bayan Saeed
Alnasser, Layla
Alanazi, Faisal
Almatar, Ahmed
Alqahtani, Ashwag Sultan
Bohlega, Balsam Saeed
Moria, Yosra
Alzahrani, Ali
author_sort Mukhtar, Noha
collection PubMed
description The incidence of differentiated thyroid cancer (DTC) is increasing worldwide. Most of the available data came from Western populations. Therefore, data from other populations are important for comparison and understanding of the spectrum of DTC worldwide. In Saudi Arabia, DTC is the 3(rd) most common cancer in general and the second most common in females after breast cancer. King Faisal Specialist Hospital and Research Centre is the main tertiary care referral center that manages the vast majority of DTC in the country. In this study, we describe the clinical and histopathological features and the management and outcome of a large series of 814 patients (pts) managed during the period Jan. 2004-Dec. 2006. Data were collected from electronic medical records. Thirty-seven pts were medullary and anaplastic thyroid cancers and 31 pts had incomplete data and were excluded from further analysis. The remaining 746 pts of DTC were studied in detail. There were 154 males (20.6%) and 592 females (79.4%). The median (range) age at the time of diagnosis was 38 years (6-83). Total thyroidectomy was performed in 719 pts (96.4%) while the other 27 pts had partial thyroid surgery. Central and/or lateral lymph node dissection was performed in 545 pts (73%). The tumors were classic papillary thyroid cancer (PTC) in 539 (72.3%) pts, follicular variant PTC in 103 (13.8%), tall cell variant PTC in 22 (2.9%), diffuse sclerosing type PTC in 10 (1.3%), follicular thyroid cancer (FTC) in 22 (2.9%). Hurthle cell cancer in 10 pts (1.3%) and 35 (4.7%) pts with other types of TC. The median tumor size is 2.0 cm (range 0.1-13). The tumors were multifocal in 307 (41.2%), had extrathyroidal extension in 299 (40%) and lymphovascular invasion in 161 pts (21.6%). Minimal to extensive lymph node resection/dissection was performed in 545 pts (73%) and was positive in 323 pts (43.3% of total pts and 59% of those who underwent LN dissection). Distant metastases were found in 96 pts (12.9%). Using TNM staging system version 8, 602 pts (80.7%) had stage 1, 73 (9.8%) stage 2, 11 (1.5%) stage 3, 1 (0.1%) stage 4a, 37 (4.9%) stage 4b and 22 (1.9%) unstageable. Radioactive iodine (I-131) ablation/therapy was given to 646 pts (86.6%) with a median administered activity of 147 mCi (range 14-302). Additional therapies were given to 187 pts and included additional RAI, surgeries and/or external irradiation. Over a median follow up of 7.6 yrs (0.5-13.2), the final outcome was as follows: 432 (58%) were in excellent status, 92 pts (12.3%) in an indeterminate status, 23 pts (3.1%) with biochemically incomplete status, 63 pts (8.4%) with structurally incomplete disease. Death due to DTC occurred in 31 pts (4.2%) while 103 pts (13.8%) were lost for follow up and their status is not clear. Conclusions: Compared with data from North America and Europe, DTC in Saudi Arabia occurs at a much earlier age, is frequently metastatic at presentation and is associated with a higher mortality.
format Online
Article
Text
id pubmed-7209198
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72091982020-05-13 MON-531 Thyroid Cancer in Saudi Arabia: Clinical and Histopathological Features, Management and Outcome of a Large Series Mukhtar, Noha Albalawi, Lina Nasser Mazi, Sedra Aljamei, Hadeel Salah Fadel, Roqyah Amer, Lama Ghassan Elsayed, Tarek AlQarni, Bayan Saeed Alnasser, Layla Alanazi, Faisal Almatar, Ahmed Alqahtani, Ashwag Sultan Bohlega, Balsam Saeed Moria, Yosra Alzahrani, Ali J Endocr Soc Thyroid The incidence of differentiated thyroid cancer (DTC) is increasing worldwide. Most of the available data came from Western populations. Therefore, data from other populations are important for comparison and understanding of the spectrum of DTC worldwide. In Saudi Arabia, DTC is the 3(rd) most common cancer in general and the second most common in females after breast cancer. King Faisal Specialist Hospital and Research Centre is the main tertiary care referral center that manages the vast majority of DTC in the country. In this study, we describe the clinical and histopathological features and the management and outcome of a large series of 814 patients (pts) managed during the period Jan. 2004-Dec. 2006. Data were collected from electronic medical records. Thirty-seven pts were medullary and anaplastic thyroid cancers and 31 pts had incomplete data and were excluded from further analysis. The remaining 746 pts of DTC were studied in detail. There were 154 males (20.6%) and 592 females (79.4%). The median (range) age at the time of diagnosis was 38 years (6-83). Total thyroidectomy was performed in 719 pts (96.4%) while the other 27 pts had partial thyroid surgery. Central and/or lateral lymph node dissection was performed in 545 pts (73%). The tumors were classic papillary thyroid cancer (PTC) in 539 (72.3%) pts, follicular variant PTC in 103 (13.8%), tall cell variant PTC in 22 (2.9%), diffuse sclerosing type PTC in 10 (1.3%), follicular thyroid cancer (FTC) in 22 (2.9%). Hurthle cell cancer in 10 pts (1.3%) and 35 (4.7%) pts with other types of TC. The median tumor size is 2.0 cm (range 0.1-13). The tumors were multifocal in 307 (41.2%), had extrathyroidal extension in 299 (40%) and lymphovascular invasion in 161 pts (21.6%). Minimal to extensive lymph node resection/dissection was performed in 545 pts (73%) and was positive in 323 pts (43.3% of total pts and 59% of those who underwent LN dissection). Distant metastases were found in 96 pts (12.9%). Using TNM staging system version 8, 602 pts (80.7%) had stage 1, 73 (9.8%) stage 2, 11 (1.5%) stage 3, 1 (0.1%) stage 4a, 37 (4.9%) stage 4b and 22 (1.9%) unstageable. Radioactive iodine (I-131) ablation/therapy was given to 646 pts (86.6%) with a median administered activity of 147 mCi (range 14-302). Additional therapies were given to 187 pts and included additional RAI, surgeries and/or external irradiation. Over a median follow up of 7.6 yrs (0.5-13.2), the final outcome was as follows: 432 (58%) were in excellent status, 92 pts (12.3%) in an indeterminate status, 23 pts (3.1%) with biochemically incomplete status, 63 pts (8.4%) with structurally incomplete disease. Death due to DTC occurred in 31 pts (4.2%) while 103 pts (13.8%) were lost for follow up and their status is not clear. Conclusions: Compared with data from North America and Europe, DTC in Saudi Arabia occurs at a much earlier age, is frequently metastatic at presentation and is associated with a higher mortality. Oxford University Press 2020-05-08 /pmc/articles/PMC7209198/ http://dx.doi.org/10.1210/jendso/bvaa046.787 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Thyroid
Mukhtar, Noha
Albalawi, Lina Nasser
Mazi, Sedra
Aljamei, Hadeel Salah
Fadel, Roqyah
Amer, Lama Ghassan
Elsayed, Tarek
AlQarni, Bayan Saeed
Alnasser, Layla
Alanazi, Faisal
Almatar, Ahmed
Alqahtani, Ashwag Sultan
Bohlega, Balsam Saeed
Moria, Yosra
Alzahrani, Ali
MON-531 Thyroid Cancer in Saudi Arabia: Clinical and Histopathological Features, Management and Outcome of a Large Series
title MON-531 Thyroid Cancer in Saudi Arabia: Clinical and Histopathological Features, Management and Outcome of a Large Series
title_full MON-531 Thyroid Cancer in Saudi Arabia: Clinical and Histopathological Features, Management and Outcome of a Large Series
title_fullStr MON-531 Thyroid Cancer in Saudi Arabia: Clinical and Histopathological Features, Management and Outcome of a Large Series
title_full_unstemmed MON-531 Thyroid Cancer in Saudi Arabia: Clinical and Histopathological Features, Management and Outcome of a Large Series
title_short MON-531 Thyroid Cancer in Saudi Arabia: Clinical and Histopathological Features, Management and Outcome of a Large Series
title_sort mon-531 thyroid cancer in saudi arabia: clinical and histopathological features, management and outcome of a large series
topic Thyroid
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209198/
http://dx.doi.org/10.1210/jendso/bvaa046.787
work_keys_str_mv AT mukhtarnoha mon531thyroidcancerinsaudiarabiaclinicalandhistopathologicalfeaturesmanagementandoutcomeofalargeseries
AT albalawilinanasser mon531thyroidcancerinsaudiarabiaclinicalandhistopathologicalfeaturesmanagementandoutcomeofalargeseries
AT mazisedra mon531thyroidcancerinsaudiarabiaclinicalandhistopathologicalfeaturesmanagementandoutcomeofalargeseries
AT aljameihadeelsalah mon531thyroidcancerinsaudiarabiaclinicalandhistopathologicalfeaturesmanagementandoutcomeofalargeseries
AT fadelroqyah mon531thyroidcancerinsaudiarabiaclinicalandhistopathologicalfeaturesmanagementandoutcomeofalargeseries
AT amerlamaghassan mon531thyroidcancerinsaudiarabiaclinicalandhistopathologicalfeaturesmanagementandoutcomeofalargeseries
AT elsayedtarek mon531thyroidcancerinsaudiarabiaclinicalandhistopathologicalfeaturesmanagementandoutcomeofalargeseries
AT alqarnibayansaeed mon531thyroidcancerinsaudiarabiaclinicalandhistopathologicalfeaturesmanagementandoutcomeofalargeseries
AT alnasserlayla mon531thyroidcancerinsaudiarabiaclinicalandhistopathologicalfeaturesmanagementandoutcomeofalargeseries
AT alanazifaisal mon531thyroidcancerinsaudiarabiaclinicalandhistopathologicalfeaturesmanagementandoutcomeofalargeseries
AT almatarahmed mon531thyroidcancerinsaudiarabiaclinicalandhistopathologicalfeaturesmanagementandoutcomeofalargeseries
AT alqahtaniashwagsultan mon531thyroidcancerinsaudiarabiaclinicalandhistopathologicalfeaturesmanagementandoutcomeofalargeseries
AT bohlegabalsamsaeed mon531thyroidcancerinsaudiarabiaclinicalandhistopathologicalfeaturesmanagementandoutcomeofalargeseries
AT moriayosra mon531thyroidcancerinsaudiarabiaclinicalandhistopathologicalfeaturesmanagementandoutcomeofalargeseries
AT alzahraniali mon531thyroidcancerinsaudiarabiaclinicalandhistopathologicalfeaturesmanagementandoutcomeofalargeseries